Synthetic biology vs traditional chemical synthesis: cost, yield, and sustainability compared

Why It Matters

The global chemicals industry produces over 2.3 billion tonnes of product annually and is responsible for approximately 6% of worldwide CO₂ emissions, making it the third-largest industrial emitter after steel and cement (IEA, 2025). Traditional petrochemical synthesis has dominated this landscape for a century, converting fossil feedstocks into everything from plastics to pharmaceuticals with well-characterized yields and mature supply chains. Yet synthetic biology is now challenging that dominance. The global synthetic biology market reached $18.9 billion in 2025 and is forecast to exceed $50 billion by 2030, driven by engineered microorganisms that convert renewable feedstocks into high-value chemicals at ambient temperatures and atmospheric pressure (McKinsey, 2025). Ginkgo Bioworks reported in early 2026 that its cell programming platform had designed over 150 commercial organisms across more than 40 end markets, underscoring how rapidly biomanufacturing is scaling.

For sustainability professionals, the choice between these two production paradigms involves trade-offs across cost, yield, carbon intensity, scalability, and supply chain resilience. Neither approach is universally superior. Understanding where synthetic biology outperforms traditional synthesis, and where petrochemistry retains structural advantages, is critical for procurement decisions, capital planning, and credible decarbonization strategies.

Key Concepts

Traditional chemical synthesis. Conventional synthesis converts petroleum or natural gas derivatives into target molecules through sequences of catalytic reactions at elevated temperatures (100 to 1,000°C) and pressures (1 to 300 atm). The technology benefits from over a century of process optimization, massive installed capacity, and feedstock costs that track global oil and gas markets. Commodity chemicals like ethylene, propylene, and methanol are produced at scales exceeding 100 million tonnes per year with atom efficiencies of 60 to 85% (American Chemical Society, 2024).

Synthetic biology platforms. Synthetic biology uses genetically engineered microorganisms (bacteria, yeast, or algae) to convert sugars, CO₂, or waste streams into target molecules through metabolic pathways. The design-build-test-learn (DBTL) cycle enables iterative optimization of microbial strains. Modern platforms can achieve titers above 100 g/L for molecules like 1,3-propanediol and succinic acid, approaching economic competitiveness with petrochemical routes for select products (Amyris, 2025). Fermentation typically operates at 25 to 37°C and atmospheric pressure, dramatically reducing energy inputs per kilogram of product.

Feedstock flexibility. Traditional synthesis depends on fossil feedstocks whose prices are volatile and whose extraction carries environmental externalities. Synthetic biology can use first-generation feedstocks (sugars from corn or sugarcane), second-generation feedstocks (lignocellulosic biomass), or emerging third-generation inputs (CO₂ and methane). LanzaTech's gas fermentation platform, for example, converts industrial waste gases containing carbon monoxide into ethanol and other chemicals, effectively turning emissions into products (LanzaTech, 2025).

Scale considerations. The largest petrochemical crackers process 1 to 2 million tonnes of feedstock annually. By contrast, the largest fermentation facilities operate at 200,000 to 500,000 cubic meters of annual capacity. Bridging this scale gap requires capital-intensive bioreactor construction and downstream processing infrastructure that remains a primary bottleneck for the synthetic biology industry.

Head-to-Head Comparison

A 2025 lifecycle assessment by the European Chemicals Agency (ECHA) found that bio-based production routes for succinic acid, 1,4-butanediol, and farnesene emitted 45 to 70% less CO₂ per tonne than their petrochemical equivalents when produced using renewable energy and second-generation feedstocks (ECHA, 2025).

Cost Analysis

Petrochemical production costs. Commodity chemicals produced via traditional synthesis benefit from enormous economies of scale. Ethylene costs $800 to $1,200 per tonne from a modern steam cracker in the U.S. Gulf Coast, with cash margins of 20 to 35% at mid-cycle oil prices. Specialty chemicals carry higher margins but also higher synthesis complexity. The cost structure is dominated by feedstock (50 to 70% of total) and energy (15 to 25%), making it highly sensitive to fossil fuel prices.

Biomanufacturing costs. Fermentation-based production currently costs 1.5 to 3 times more than petrochemical routes for most commodity molecules. Feedstock (sugar or biomass) accounts for 30 to 50% of costs, while downstream processing (separation, purification) contributes 20 to 40%. However, costs are declining rapidly. Solugen demonstrated in 2025 that its chemienzymatic platform produces glucaric acid at cost parity with petroleum-derived adipic acid, a $7 billion market, by eliminating the need for high-pressure catalysis (Solugen, 2025). Genomatica reported production of bio-based 1,4-butanediol at less than $1,500 per tonne in 2025, narrowing the gap with petrochemical BDO priced at $1,200 to $1,400 per tonne (Genomatica, 2025).

Carbon cost implications. As carbon pricing expands globally, the cost calculus shifts further toward biological production. The EU Emissions Trading System reached a sustained price above €70 per tonne CO₂ in 2025, adding $70 to $350 per tonne of product cost to petrochemical processes depending on emission intensity (EU ETS, 2025). When carbon costs are internalized, bio-based routes for molecules like succinic acid and lactic acid already achieve total-cost parity with traditional synthesis in European markets.

Capital efficiency. Synthetic biology companies are increasingly partnering with contract manufacturers (CDMOs) to avoid the capital burden of building dedicated facilities. Companies like National Resilience and Samsung Biologics now offer large-scale fermentation capacity on a contract basis, reducing the capital required for a synthetic biology startup to bring a new molecule to market from $200 million to as little as $20 million for the organism development phase alone.

Use Cases and Best Fit

Traditional synthesis excels in: ultra-high-volume commodity chemicals (ethylene, methanol, ammonia) where scale economics are decisive; molecules that require extreme reaction conditions incompatible with biological systems; products with well-established supply chains and customer specifications tied to petrochemical-grade purity; and geographies with abundant low-cost natural gas feedstock such as the U.S. Gulf Coast and the Middle East.

Synthetic biology excels in: high-value specialty chemicals and ingredients where premium pricing compensates for higher unit costs, such as fragrances, flavors, and cosmetic actives. Amyris (now part of the Givaudan supply chain) produces squalane from engineered yeast at $5 to $8 per kilogram versus $15 to $30 per kilogram from shark liver oil, simultaneously eliminating an animal welfare concern (Amyris, 2025). Synthetic biology also excels in novel molecules with no existing petrochemical route; products where sustainability credentials command a market premium (bio-based nylon, bio-surfactants); and applications requiring stereochemical precision that is difficult to achieve with traditional catalysis.

Emerging convergence. Several organizations are blending both approaches. BASF partnered with Genomatica in 2024 to produce bio-based 1,4-butanediol at its Ludwigshafen complex, using existing downstream infrastructure with a biological front end. Novamont operates a fully integrated biorefinery in Porto Torres, Sardinia, converting thistle oil into bio-based monomers for biodegradable plastics at 100,000 tonnes per year, demonstrating that synbio-derived intermediates can feed into conventional polymer processing (Novamont, 2025).

Decision Framework

Organizations evaluating synthetic biology versus traditional chemical synthesis should assess five dimensions:

1. Molecule complexity and value. For molecules priced above $3 per kilogram with complex stereochemistry, synthetic biology routes are often economically viable today. For molecules below $1 per kilogram produced at volumes exceeding 500,000 tonnes per year, traditional synthesis retains a decisive cost advantage.

2. Carbon exposure. Quantify the carbon cost embedded in your current supply chain. If carbon pricing adds more than 10% to your production costs, evaluate bio-based alternatives for the highest-emission molecules first.

3. Feedstock risk. Assess volatility in your petrochemical feedstock costs over the past five years. If feedstock price swings exceed 30%, bio-based routes using locally sourced sugars or waste streams can provide supply chain stability.

4. Regulatory trajectory. The EU's REACH regulation and the proposed U.S. TSCA modernization both favor chemicals produced with lower hazard profiles. Bio-based routes that avoid hazardous solvents and heavy-metal catalysts can reduce regulatory compliance costs by 20 to 40%.

5. Customer sustainability requirements. Survey your top 10 customers' procurement specifications. If more than half have published sustainable procurement policies requiring bio-based content, lifecycle assessments, or Scope 3 reduction targets, investing in biological production capacity provides a competitive moat.

Key Players

Established Leaders

• BASF — Partnered with Genomatica for bio-BDO production. Operates bio-based surfactant and enzyme portfolios at industrial scale.
• Dow — Produces bio-based polyethylene from sugarcane ethanol in Brazil. 350,000 tonnes/year capacity.
• DSM-Firmenich — Leading bio-based ingredient producer for nutrition, health, and fragrance markets. Extensive fermentation infrastructure.
• Novamont — Integrated biorefinery producing Mater-Bi biodegradable plastics from renewable feedstocks at 100,000+ tonnes/year.

Emerging Startups

• Solugen — Chemienzymatic platform producing commodity chemicals (glucaric acid, hydrogen peroxide) at cost parity with petrochemicals.
• LanzaTech — Gas fermentation converting industrial waste CO and CO₂ into ethanol and chemicals. Partnerships with ArcelorMittal and Zara.
• Ginkgo Bioworks — Cell programming foundry designing engineered organisms across 40+ markets. 150+ commercial programs.
• Zymergen (acquired by Ginkgo) — Materials-focused synthetic biology platform now integrated into Ginkgo's organism design capabilities.

Key Investors/Funders

• Breakthrough Energy Ventures — Portfolio includes Solugen, Pivot Bio, and other bio-based chemical companies.
• SOSV/IndieBio — Leading synthetic biology accelerator with 180+ portfolio companies.
• Temasek — Major investor in Ginkgo Bioworks and multiple bio-based materials companies.

FAQ

Can synthetic biology match the scale of petrochemical plants? Not yet for commodity chemicals. The largest fermentation facilities produce 50,000 to 200,000 tonnes per year, compared with over 1 million tonnes for world-scale petrochemical plants. However, the gap is closing. LanzaTech's commercial facility in Shougang, China processes 46,000 tonnes of ethanol per year from steel mill waste gas, and the company has announced plans for a 100,000 tonne facility by 2028. For specialty chemicals produced at 10,000 to 50,000 tonnes per year, synthetic biology already competes effectively on scale.

How do feedstock costs compare? Petrochemical feedstock costs are highly correlated with crude oil and natural gas prices, averaging $200 to $600 per tonne for naphtha. Fermentation feedstocks (industrial-grade sugar) cost $250 to $400 per tonne globally, with significant regional variation. When using second-generation feedstocks like corn stover or sugarcane bagasse, costs can drop to $80 to $150 per tonne, but pretreatment adds processing costs. The net effect is that feedstock costs are roughly comparable, but biological routes offer greater price stability because agricultural commodity markets are less volatile than petroleum markets.

What is the carbon footprint difference? Across molecules studied in the ECHA 2025 lifecycle assessment, bio-based routes emit 45 to 70% less CO₂ per tonne than petrochemical equivalents when powered by renewable energy. The advantage narrows to 20 to 35% when grid electricity with a higher carbon intensity is used. For molecules where the microorganism directly fixes CO₂ as a feedstock, such as in LanzaTech's gas fermentation process, the production pathway can be carbon-negative on a cradle-to-gate basis.

How long does it take to develop a new bio-based production route? The DBTL cycle has accelerated significantly. Five years ago, developing a commercially viable microbial strain took 5 to 7 years. With AI-assisted protein engineering tools from companies like Ginkgo Bioworks and Arzeda, strain development timelines have compressed to 2 to 4 years. Arzeda reported in 2025 that its computational enzyme design platform reduced the number of physical experiments needed by 80%, cutting development costs by 60% (Arzeda, 2025).

Are bio-based chemicals truly "drop-in" replacements? For many molecules, yes. Bio-based 1,3-propanediol (used in polymers and cosmetics), succinic acid (used in plasticizers and coatings), and lactic acid (used in bioplastics) are chemically identical to their petrochemical equivalents and require no reformulation by downstream users. However, some bio-based products contain trace impurities from fermentation that may require additional purification for sensitive applications like electronics-grade solvents or pharmaceutical intermediates.

Sources

• International Energy Agency. (2025). The Future of Petrochemicals: Towards a More Sustainable Chemical Industry. IEA.
• McKinsey & Company. (2025). Synthetic Biology: Market Sizing and Growth Projections to 2030. McKinsey Global Institute.
• American Chemical Society. (2024). Industrial Chemical Production: Scale, Efficiency, and Environmental Impact. ACS Green Chemistry.
• European Chemicals Agency. (2025). Lifecycle Assessment of Bio-Based vs. Petrochemical Production Routes for Key Platform Chemicals. ECHA.
• Solugen. (2025). Chemienzymatic Production Economics: Achieving Cost Parity for Glucaric Acid. Solugen Technical Report.
• Genomatica. (2025). Bio-Based 1,4-Butanediol: Commercial-Scale Production Metrics and Cost Trajectory. Genomatica.
• LanzaTech. (2025). Gas Fermentation at Scale: Shougang Commercial Operations Update. LanzaTech.
• Amyris. (2025). Fermentation-Derived Squalane: Cost and Sustainability Benchmarks. Amyris / Givaudan.
• Novamont. (2025). Porto Torres Biorefinery: Operational Performance and Circular Economy Metrics. Novamont.
• Arzeda. (2025). Computational Enzyme Design: Accelerating the DBTL Cycle for Industrial Biocatalysis. Arzeda.
• EU Emissions Trading System. (2025). Carbon Price Trends and Industrial Impact Analysis. European Commission.